Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis

Journal of Internal Medicine

Volumn 265, Issue 4, 2009, Pages 459-464

  Mattsson, N ^b   Yaong, M ^a   Rosengren, L ^b   Blennow, K ^b   Mansson J E ^b   Andersen, O ^b   Zetterberg, H ^b   Haghighi, S ^b   Zho, I ^a   Pratico, D ^a  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

15 (S) Hydroxyeicosatetraenoic acid; Arachidonic acid; Biomarker; Inflammation; Prostaglandin E2

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; BIOLOGICAL MARKER; PROSTAGLANDIN E2;

ADULT; ARTICLE; AXONAL INJURY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 61849133439     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.02035.x     Document Type: Article

References (30)

1. Martino G, Adorini L, Rieckmann P et al. Inflammation in multiple sclerosis: the good, the bad and the complex. Lancet Neurol 2002 1 : 499 509.
2. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993 11 : 371 86.
3. O'Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD. Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem 1996 66 : 2532 40.
4. Shappell SB, Gupta RA, Manning S et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001 61 : 497 503.
5. Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta 2007 1771 : 1031 45.
6. Snijdewint FG, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 1993 150 : 5321 9.
7. Dore-Duffy P, Ho SY, Donovan C. Cerebrospinal fluid eicosanoid levels: endogenous PGD2 and LTC4 synthesis by antigen-presenting cells that migrate to the central nervous system. Neurology 1991 41 : 322 4.
8. Greco A, Minghetti L, Sette G, Fieschi C, Levi G. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 1999 53 : 1876 9.
9. Greco A, Minghetti L, Puopolo M et al. Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. J Neurol Sci 2004 224 : 23 7.
10. Haghighi S, Andersen O, Rosengren L, Bergstrom T, Wahlstrom J, Nilsson S. Incidence of CSF abnormalities in siblings of multiple sclerosis patients and unrelated controls. J Neurol 2000 247 : 616 22.
11. Svenningsson A, Runmarker B, Lycke J, Andersen O. Incidence of multiple sclerosis during two fifteen-year periods in the Göteborg region of Sweden. Acta Neurol Scand 1996 82 : 161 8.
12. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 13 : 227 31.
13. Poser CM. Pathogenesis of multiple sclerosis. A critical reappraisal. Acta Neuropathol 1986 71 : 1 10.
14. Poser CM. The pathogenesis of multiple sclerosis. Additional considerations. J Neurol Sci 1993 115 : S3 15.
15. Haghighi S, Frisén L, Odén A, Andersen O. Multiple sclerosis siblings with cerebrospinal fluid immunopathy but without any indication of neuronal damage. Acta Neurol Scand 2003 108 : 319 22.
16. Haghighi S, Andersen O, Odén A, Rosengren L. Cerebrospinal fluid markers in MS patients and their healthy siblings. Acta Neurol Scand 2004 109 : 97 9.
17. Callander M, Haghighi S, Landtblom AM et al. Multiple sclerosis immunopathic trait and HLA-DR(2)15 as independent risk factors in multiple sclerosis. Mult Scler 2007 13 : 441 5.
18. Mattsson N, Haghighi S, Andersen O et al. Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci Lett 2007 414 : 233 6.
19. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000 48 : 809 12.
20. Yao Y, Clark CM, Trojanowski JQ, Lee VM, Pratico D. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 2005 58 : 623 6.
21. Ilzecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand 2003 108 : 125 9.
22. Mustafa MM, Ramilo O, Sáez-Llorens X, Olsen KD, Magness RR, McCracken GH Jr. Cerebrospinal fluid prostaglandins, interleukin 1 beta, and tumor necrosis factor in bacterial meningitis. Clinical and laboratory correlations in placebo-treated and dexamethasone-treated patients. Am J Dis Child 1990 144 : 883 7.
23. Almer G, Teismann P, Stevic Z et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 2002 58 : 1277 9.
24. Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 1995 133 : 61 5.
25. Petzold A, Eikelenboom MJ, Gveric D et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002 125 : 1462 73.
26. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003 987 : 25 31.
27. Van Geel WJ, Rosengren LE, Verbeek MM. An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods 2005 296 : 179 85.
28. Bolton C, Turner AM, Turk JL. Prostaglandin levels in cerebrospinal fluid from multiple sclerosis patients in remission and relapse. J Neuroimmunol 1984 6 : 151 9.
29. Dore-Duffy P, Donaldson JO, Koff T, Longo M, Perry W. Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology 1986 36 : 1587 90.
30. Ni J, Shu YY, Zhu YN et al. COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J Neuroimmunol 2007 186 : 94 103.